F8A3 Inhibitors
The chemical class of F8A3 Inhibitors encompasses a variety of compounds capable of potentially inhibiting the activity of the F8A3 protein, either directly or indirectly. F8A3 is likely involved in several signaling pathways crucial for cell growth, proliferation, and survival, including those regulated by tyrosine kinases, mammalian target of rapamycin (mTOR), mitogen-activated protein kinase kinase (MEK), and Janus kinase (JAK). Therefore, inhibitors such as afatinib, crizotinib, sorafenib, and erlotinib, which target tyrosine kinases, can potentially inhibit F8A3 by blocking the activity of these key mediators of cellular signaling. By disrupting downstream signaling events, these inhibitors may regulate F8A3 expression or function, ultimately influencing its activity within the cellular context.
Additionally, compounds like everolimus, trametinib, and ruxolitinib offer potential avenues for F8A3 inhibition by targeting mTOR, MEK, and JAK, respectively. By inhibiting these signaling pathways, these inhibitors can disrupt the activation of downstream effectors implicated in F8A3 regulation, leading to indirect inhibition of F8A3 activity. Furthermore, multi-targeted inhibitors such as lapatinib, vandetanib, cabozantinib, sunitinib, and dasatinib, which block the activity of multiple tyrosine kinases involved in cell signaling pathways, provide additional strategies for potential F8A3 inhibition. Overall, these inhibitors represent valuable tools for further elucidating the biochemical and physiological roles of F8A3.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Afatinib-d4 | 850140-72-6 (unlabeled) | sc-481821 | 10 mg | $4665.00 | ||
Afatinib is a tyrosine kinase inhibitor that can potentially inhibit F8A3 by blocking the activity of various tyrosine kinases involved in cell signaling pathways. By inhibiting tyrosine kinase activity, afatinib can disrupt downstream signaling events that may regulate F8A3 expression or function, ultimately influencing its activity within the cellular context. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus is a mammalian target of rapamycin (mTOR) inhibitor that can potentially inhibit F8A3 by blocking mTOR activity. By inhibiting mTOR, everolimus can disrupt downstream signaling pathways regulating cell growth, proliferation, and survival. Indirect inhibition of F8A3 may occur through modulation of mTOR-dependent pathways that influence F8A3 expression or function within the cellular context. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-targeted kinase inhibitor that can potentially inhibit F8A3 by blocking the activity of various tyrosine kinases and serine/threonine kinases involved in cell signaling pathways. By inhibiting kinase activity, sorafenib can disrupt downstream signaling events that may regulate F8A3 expression or function, ultimately influencing its activity within the cellular context. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is a tyrosine kinase inhibitor that can potentially inhibit F8A3 by blocking the activity of various tyrosine kinases involved in cell signaling pathways. By inhibiting tyrosine kinase activity, erlotinib can disrupt downstream signaling events that may regulate F8A3 expression or function, ultimately influencing its activity within the cellular context. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor that can potentially inhibit F8A3 by blocking the activity of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). By inhibiting tyrosine kinase activity, lapatinib can disrupt downstream signaling events that may regulate F8A3 expression or function, ultimately influencing its activity within the cellular context. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a specific inhibitor of mitogen-activated protein kinase kinase (MEK), an upstream activator of extracellular signal-regulated kinases 1 and 2 (ERK1/2). Inhibition of MEK by trametinib can disrupt the activation of ERK1/2 signaling pathways, potentially leading to indirect inhibition of F8A3, which may be regulated by ERK1/2-dependent pathways. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib is a tyrosine kinase inhibitor that can potentially inhibit F8A3 by blocking the activity of various tyrosine kinases involved in cell signaling pathways. By inhibiting tyrosine kinase activity, vandetanib can disrupt downstream signaling events that may regulate F8A3 expression or function, ultimately influencing its activity within the cellular context. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that can potentially inhibit F8A3 by blocking the activity of various tyrosine kinases involved in cell signaling pathways. By inhibiting tyrosine kinase activity, cabozantinib can disrupt downstream signaling events that may regulate F8A3 expression or function, ultimately influencing its activity within the cellular context. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a selective Janus kinase (JAK) inhibitor that can potentially inhibit F8A3 by blocking JAK activity. By inhibiting JAK, ruxolitinib can disrupt downstream signaling events that may regulate F8A3 expression or function, ultimately influencing its activity within the cellular context. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a multi-targeted tyrosine kinase inhibitor that can potentially inhibit F8A3 by blocking the activity of various tyrosine kinases involved in cell signaling pathways. By inhibiting tyrosine kinase activity, sunitinib can disrupt downstream signaling events that may regulate F8A3 expression or function, ultimately influencing its activity within the cellular context. | ||||||